Ricardo Perdigão Henriques
Managing Partner @ Biovance Capital
Lisbon, Portugal
Ricardo Perdigão Henriques is a seed investor at Biovance Capital in Lisbon focused on Medical and Biotechnology. Ricardo is co-founder and Managing Partner of Biovance Capital, a new € 51M fund to invest in early-stage biotech companies across Europe developing innovative therapeutics in all disease areas and drug modalities (small and large molecules, vaccines, cell, and gene therapies). Ricardo is a Harvard and MIT-educated scientist turned investor with experience in scientific research, drug development, venture capital licensing, business development and market analysis. Ricardo has over 18 years of experience in the biomedical sector in USA and Portugal. Prior to Biovance Capital, he was the CEO of Bionova Capital, a venture capital firm that invested in health startups across Europe. At Bionova, he invested in the oncology startup CellmAbs that was sold to BioNTech potentially for more than € 1 billion, the largest-ever biotech deal in Portugal. Ricardo was previously an international business analyst at BIAL, an international R&D-based pharmaceutical company headquartered in Portugal that has developed two proprietary CNS drugs currently in the global market. Ricardo was an investment manager at Portugal Ventures where he managed a portfolio of dix biotech companies and scouted for new deals. Portugal Ventures is the largest venture capital firm in Portugal with 100+ portfolio companies. Ricardo performed his PhD work at the Harvard Medical School (Prof. Judy Lieberman's laboratory). There, he studied the process of breast cancer metastasis and discovered hundreds of previously unknown genes regulated by the microRNA-200 family that are involved in the metastatic process. He also generated the first-ever genome-wide map of microRNA-200 target genes and this map has been helping the scientific community to better understand the important role of this microRNA family in cancer. His research has been published in prestigious journals such as Nature Publishing Group's Oncogene, Journal of Clinical Investigation and Biotechnology Progress. Ricardo was also a researcher at the Massachusetts Institute of Technology where he developed a new tool (micro-bioreactors) to identify high-producing cells for antibody manufacturing. Ricardo holds a B.Sc. in Biochemistry and a Ph.D. in Molecular Biology, both approved with the Highest Honors.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Ricardo Perdigão Henriques invests in
Stages Ricardo Perdigão Henriques invests in
Countries Ricardo Perdigão Henriques invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (50%)
- Biotechnology 2 (50%)
- Pharmaceutical 1 (25%)
- Product Research 1 (25%)
Stage
- Seed 2 (50%)
- Series A 2 (50%)
Country
- Portugal 2 (50%)
- Spain 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vaxdyn develops vaccines using novel technology. They offers pathogen vaccines for preventing antibiotics-resistant infections. Their customers' inquiries are addressed through phone, email, and online applications. | $12.8M / Series A / Sep 07, 2026 | ||
| Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | Series A / Sep 18, 2025 | ||
| Vaxdyn develops vaccines using novel technology. They offers pathogen vaccines for preventing antibiotics-resistant infections. Their customers' inquiries are addressed through phone, email, and online applications. | $355.5K / Seed / Mar 08, 2021 | ||
| Pharmaceutical Company, Biotechnology | $1.6M / Seed / Jun 25, 2019 |
Co-Investors
About Biovance Capital
Biovance Capital is a new € 51M fund to invest in early-stage biotech companies across Europe developing innovative therapeutics in all disease areas and drug modalities (small and large molecules, vaccines, cell, and gene therapies).
Biovance Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joao Incio
General Partner
|
|||
|
Ricardo Perdigão Henriques
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ricardo Perdigão Henriques invest in?
Ricardo Perdigão Henriques invests primarily in Medical, Biotechnology and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Portugal. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ricardo Perdigão Henriques?
Public channels for Ricardo Perdigão Henriques include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ricardo Perdigão Henriques last invest?
The most recent investment recorded for Ricardo Perdigão Henriques closed in Sep 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
